Saturday, October 31, 2026

Trump announces military will Establish a space force

Jessica Wettig

June 20, 2018

Donald Trump. Photo by: Gage Skidmore.
WASHINGTON (ViaNews) - President Donald J. Trump announced that there will be a sixth branch of U.S. Military: A space force. This announcement has immediately raised questions for people, but the president has only provided so much information. According to CBS News, he announced this at the National Space Council Meeting at the White House. He also signed a new Space Policy Directive, which will establish new protocols and procedures to manage and monitor the satellites in low-Earth orbit. This also includes the 10,000+ space debris that poses a high risk to spacecraft. In addition, there are two other space initiatives being enforced by the National Space Council. One of these initiatives seeks to place more men on the moon and eventually place them on Mars. Another initiative calls for streamlining the federal space bureaucracy to decrease red tape and streamline licensing and oversight of commercial space activity. Trump essentially seeks for America to dominate space. He said this plan not only regards national identity but national security. “It's not enough to merely have an American presence in space; We must have American dominance in space,” said Trump. Now, it's well-known that NASA and the American government has always wanted dominance in space. After all, we made sure we were the first to put a man on the moon. But, a space force is a very big plan. Trump does not yet have congressional support, and the process will require this along with an established plan. Trump did not declare any details or plan for this new establishment. The U.S. Air Force currently handles all the space capabilities. According to ABC News, the National Defense Authorization Act (NDAA) has a purpose to establish a fighting force, specifically space war-fighting. It also required the Secretary of Air Force to increase the amount and improve the quality of its civilian and military space cadre. However, the Senate's bill says nothing about a space force, but according to a source the NDAA gave the Air Force a “pretty significant homework assignment.” For several months, the Department of Defense has been doing work on an ongoing review that seeks to establish a space force separate from the Air Force. Details on this have not been released to the public. Several members of Congress have tweeted their opposition to creating a space force, including Democratic Senator Bill Nelson, who said that the generals he has talked to declared they do not support the idea either. He said that now is not the time to rip the Air Force apart. Secretary Jim Mattis said he was also opposed to the idea in a letter last summer to Representative Mike Turner of Ohio. He said right now they are trying to integrate the department's war-fighting functions and that this “separate service would likely present a narrower and even parochial approach to space operations.” However, he seems to have become more open to the idea. In May, he said, “But to look at the problem means we have to look afresh at it, and where are the specific problems, break them down, and if an organizational construct has to change, then I'm wide open to it.”
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com